MedTrace Logo

A Study to Measure Daridorexant in Breast Milk of Healthy Lactating Women

NCT05632393 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2023-05-12

No results posted yet for this study

Summary

A study to measure daridorexant in breast milk of healthy lactating women

Conditions

  • Healthy

Interventions

DRUG

Daridorexant

Daridorexant will be available as film-coated tablets for oral administration formulated at a strength of 50 mg.

Sponsors & Collaborators

  • Idorsia Pharmaceuticals Ltd.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Idosia Pharmaceuticals Ltd

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-01-16
Primary Completion
2023-04-30
Completion
2023-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05632393 on ClinicalTrials.gov